Income statement, balance sheet and cash flow statement for the last 9 fiscal years, taken from the XBRL data Twist Bioscience Corp files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2017
FY2019
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
10.8
25.4
54.4
90.1
132
204
245
313
377
Cost of revenue
24
32.2
47.4
61.4
80.6
119
155
180
186
Gross profit
-13.3
-6.76
6.96
28.7
51.7
84.2
89.7
133
191
Research and development
19.2
20.3
35.7
43
69.1
120
107
90.9
80.3
Selling, general and administrative
26.1
43.5
80.1
103
136
213
190
218
247
Operating income
-58.5
-70.6
-109
-140
-153
-235
-217
-221
-136
Interest expense
0.91
1.31
1.29
0.79
0.37
0.08
0.01
0.03
Interest income
0.41
1
3.03
1.5
0.44
3.06
14.4
15.3
11.4
Other non-operating income
-0.06
-0.12
-0.27
-0.18
-1.37
-1.09
-0.67
-2.68
-0.9
Pre-tax income
-59
-71
-107
-140
-154
-228
-203
-208
-77
Income tax
0.28
0.24
0.29
0.38
-1.93
-10.4
1.15
0.56
0.72
Net income
-59.3
-71.2
-108
-140
-152
-218
-205
-209
-77.7
EBITDA
-53.5
-64.8
-103
-133
-143
-218
-188
-189
-111
EPS, basic
-24.49
-25.51
-3.92
-3.57
-3.15
-4.04
-3.60
-3.60
-1.30
EPS, diluted
-24.49
-25.51
-3.92
-3.57
-3.15
-4.04
-3.60
-3.60
-1.30
Shares, basic (weighted)
2,422
0
27.5
39.2
48.3
53.9
56.9
58
59.8
Shares, diluted (weighted)
2,422
0
27.5
39.2
48.3
53.9
56.9
58
59.8
Balance sheet
FY2017
FY2019
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
31.2
80.8
46.7
93.7
466
379
286
226
183
Short-term investments
91.4
196
12
126
49.9
50.1
49.4
Receivables
5.42
12.1
26.4
28.5
40.3
44.1
34.9
57
Inventory
6.03
7.33
12.3
31.8
39.3
32.1
24.1
28.3
Other current assets
3.47
2.59
6.2
8.28
11.9
11.7
11.4
1.72
Total current assets
95.7
160
335
546
596
424
347
333
Property, plant and equipment
12.3
20.8
25.5
44.1
139
132
103
102
Lease right-of-use assets
33.7
61.6
74.9
71.5
58.8
49.4
Goodwill
1.14
1.14
1.14
22.4
85.8
85.8
85.8
82.2
Intangible assets
0.71
0.51
0.31
18.3
59.7
54.5
14.5
13.4
Long-term investments
0
Other non-current assets
5.36
3.8
2.82
7.67
3.39
5.68
1.57
4.9
Total assets
116
187
399
702
961
776
614
642
Accounts payable
7.53
9.76
4.83
14.9
20.1
14.1
1.63
11.1
Accrued liabilities
2.17
5.97
3.9
6.44
10.2
10.8
15.1
22.8
Deferred revenue
1.09
3.48
3
2.13
6.88
Short-term debt
2.5
3.33
3.33
1.55
0
Total current liabilities
18.5
30.4
36
63.1
90.7
73.3
71
91.4
Long-term debt
7.22
4.4
1.4
Lease liabilities
24.8
53.2
81.3
79.2
70.2
61.8
Other non-current liabilities
0.34
0.16
0.35
5.07
0.06
0.48
0.41
0.75
Total liabilities
26.7
34.9
62.6
121
172
153
142
169
Total debt
9.72
7.5
4.17
1.55
0
Paid-in capital
9.35
470
795
1,191
1,620
1,657
1,715
1,793
Retained earnings
-211
-319
-458
-611
-828
-1,033
-1,242
-1,320
Other comprehensive income
0.09
0.18
0.09
0.55
-1.84
-0.76
-0.52
-0.63
Shareholders' equity
-133
-201
152
336
581
789
623
473
473
Total equity
-133
-201
152
336
581
789
623
473
473
Total liabilities and equity
116
187
399
702
961
776
614
642
Shares outstanding
3.21
32.9
45.1
49.5
56.5
57.6
58.9
60.6
Cash flow statement
FY2017
FY2019
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-59.3
-71.2
-108
-140
-152
-218
-205
-209
-77.7
Depreciation and amortization
5.02
5.73
6.11
6.68
9.75
16.5
29.3
31.4
24.9
Stock-based compensation
1.89
2.96
11.2
17.1
37
79.7
30.3
50.9
64.5
Deferred income tax
0
-2.01
-11.2
0
0
0
Change in receivables
-1.62
-3.07
-6.69
-14.3
-2.2
-9.62
-4.32
8.44
-22.4
Change in inventory
-0.6
-4.2
-1.3
-4.96
-19.5
-7.54
7.24
7.99
-4.23
Change in payables
0.56
3.76
3.28
-5.51
8.54
7.38
-2.51
-11.8
9.33
Cash from operations
-51.3
-66.2
-87.9
-142
-112
-124
-142
-64.1
-47.6
Capital expenditures
-6.59
-3.69
-14.8
-9.87
-27.1
-102
-27.8
-5.08
-28
Acquisitions
0
-0.48
-8.16
0
0
Purchases of investments
-40.6
-3.52
-178
-203
-58.8
-218
-76.3
-51.9
-49.4
Sales and maturities of investments
36.9
34.5
87.5
98.1
242
100
155
53.9
50.1
Cash from investing
-9.99
27.3
-105
-115
156
-233
50.6
-3.07
-24.8
Debt issued
2.17
Debt repaid
-4.17
-2.5
-3.33
-3.33
-1.56
0
0
Cash from financing
63.8
88.8
159
304
329
271
0.91
6.89
28.5
Exchange rate effect
0.03
0.02
0.02
-0.32
-0.03
0.13
0.14
Net change in cash
2.51
50
-34.1
46.8
373
-87.1
-91
-60.1
-43.7
Free cash flow
-57.9
-69.9
-103
-152
-139
-226
-170
-69.2
-75.6
Interest paid
0.7
0.75
0.78
0.44
0.17
0.01
0
0
Income taxes paid
0.01
0.18
0.29
0.17
0.1
0.25
0.42
0.34
0.68
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $182.83 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Gross margin
52.0%
Gross profit / revenue.
Operating margin
-33.6%
Operating income / revenue.
EBITDA margin
-27.8%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
-31.5%
Pre-tax income / revenue.
Net margin
-31.7%
Net income / revenue.
FCF margin
-21.6%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-12.3%
Cash from operations / revenue.
Return on equity (ROE)
-30.7%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-20.3%
Net income / average total assets.
Return on invested capital (ROIC)
-34.9%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue
16.6%
Research and development expense / revenue.
SG&A / revenue
67.2%
Selling, general and administrative expense / revenue.
Stock-based pay / revenue
15.4%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
9.3%
Capital expenditures / revenue.
D&A / revenue
5.7%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
20.3%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
22.8%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
33.1%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y
43.2%
Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y
31.4%
Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit CAGR, 5y
46.1%
Compound annual growth of gross profit over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y
0.1%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
-15.7%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
7.1%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
4.5%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-12.6%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
10.0%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
3.1%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
3.5%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
8.8%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
2.67x
Current assets / current liabilities.
Quick ratio
1.93x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
1.39x
(Cash + short-term investments) / current liabilities.
Days inventory + days sales outstanding - days payables.
Per share
Metric
Value
How it is calculated
EPS, diluted
-$2.19
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$6.92
Revenue / diluted weighted shares.
FCF per share
-$1.49
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$0.85
Cash from operations / diluted weighted shares.
Book value per share
$7.11
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
28.1x
Market cap / revenue.
P/B
27.2x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
34.6x
Market cap / tangible book value, when positive.
EV/Sales
27.7x
Enterprise value / revenue.
FCF yield
-0.8%
Free cash flow / market cap.
Earnings yield
-1.1%
Net income / market cap (the inverse of P/E).
What was Twist Bioscience Corp's revenue in fiscal 2025?
Twist Bioscience Corp reported revenue of $376.6M for fiscal 2025, 20.3% higher than the year before.
Was Twist Bioscience Corp profitable in fiscal 2025?
No. It reported a net loss of $77.7M.
How much free cash flow did Twist Bioscience Corp generate in fiscal 2025?
Cash from operations of $47.6M minus capital expenditures of $28.0M left free cash flow of -$75.6M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.